← All trials
NCT07311057
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2025
- Primary completion
- Dec 20, 2025
- Completion date
- Dec 20, 2025
- First posted
- Dec 30, 2025
- Last posted
- Dec 30, 2025
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mashhad University of Medical SciencesLead sponsor
- Mashhad University of Medical SciencesSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.